TABLE 2. Efficacy.
| Total (n = 66) | Anlotinib (10 mg, n = 29) | Anlotinib (12 mg, n = 37) | |
|---|---|---|---|
| ORR | 14 (21.21) | 3 (10.34) | 11 (29.73) |
| DCR | 48 (72.73) | 21 (72.41) | 27 (72.97) |
| CBR | 28 (42.42) | 9 (31.03) | 19 (51.35) |
| CR | 2 (3.03) | 0 | 2 (5.41) |
| PR | 12 (18.18) | 3 (10.34) | 9 (24.32) |
| SD | 34 (51.52) | 18 (62.07) | 16 (43.24) |
| PD | 13 (19.70) | 6 (20.69) | 7 (18.92) |
| NA | 5 (7.58) | 2 (6.90) | 3 (8.11) |
Note: All data were presented as n (%).
Abbreviations: CR, complete response; DCR, disease control rate; NA, not available for efficacy assessment; ORR: objective response rate; PD, progressive disease; PR: partial response; SD: stable disease.